Latest News

Hesai Group ( NASDAQ:HSAI ) shareholders that were waiting for something to happen have been dealt a blow with a 29...

WELL Health Technologies (TSX:WELL) just reported its third quarter earnings, showing a jump in sales and a return to profitability. The company also reaffirmed strong guidance for 2025, catching investors’ attention. See our latest analysis for WELL Health Technologies. WELL Health Technologies’ upbeat guidance and sharp sales growth have come at a time when investor sentiment has clearly shifted, with the past year’s total shareholder return down 23.9% and shares recently changing hands at...

Nexans (ENXTPA:NEX) has been on investor radars lately, with stock performance showing mixed signals over the past few months. Looking at recent returns, shares have gained 6% in the last day and 2% this week. See our latest analysis for Nexans. Nexans has shown notable momentum this year, with a 20.9% share price return year to date and a 17.7% total shareholder return over the last twelve months. Recent positive moves suggest investors are responding to shifting sentiment about the...

Organto Foods Inc.'s ( CVE:OGO ) price-to-sales (or "P/S") ratio of 2.3x may not look like an appealing investment...

The board of Gamehost Inc. ( TSE:GH ) has announced that it will pay a dividend of CA$0.05 per share on the 15th of...

Lantheus Holdings (LNTH) has seen shifts in its share price over the past month, with performance reflecting broader investor sentiment in the healthcare sector. The company’s recent returns highlight a mix of steady growth and market volatility. See our latest analysis for Lantheus Holdings. After a strong run in recent years, Lantheus Holdings has faced renewed pressure, with a year-to-date share price return of -40.55% and a 1-year total shareholder return of -38.94%. This trend suggests...

PepsiCo's Board of Directors recently declared a quarterly dividend of $1.4225 per share, marking a 5% increase compared to the same period last year and continuing the company's commitment to annualized dividend growth, with the latest raise starting in June 2025. This move marks PepsiCo's 53rd consecutive annual dividend increase, underlining the company's emphasis on long-term shareholder returns despite facing ongoing challenges in the consumer beverages sector. We'll explore how...

nLIGHT, Inc. recently reported its third quarter 2025 results, showing year-over-year revenue growth to US$66.74 million and a narrowed net loss, and also provided fourth quarter revenue guidance of US$72 million to US$78 million. An important insight is that the company’s updated guidance signals ongoing momentum in both advanced development and product revenues, suggesting broader demand across its key markets. We’ll examine how nLIGHT’s improved revenue guidance and reduced net loss...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Wondering if Cloudflare is fairly priced, overvalued, or just waiting to surprise everyone? You are not alone, especially if you are watching for signs that it can still deliver outsized returns. Cloudflare shares have soared 74.3% year-to-date and over 100% in the past year, but there have also been some sharp dips. Just last week, the stock fell 13.1%. These moves come as investors react to shifting tech sector sentiment and broader discussions about the demand for digital infrastructure...

H World Group Limited ( NASDAQ:HTHT ) investors will be delighted, with the company turning in some strong numbers with...

Goodman Property Trust has reported its half-year earnings for the period ended September 30, 2025, with sales increasing to NZ$144.5 million and net income rising to NZ$61.8 million compared to the previous year. The trust highlighted strong growth in earnings per unit and maintained its full-year cash earnings guidance, emphasizing resilience despite economic challenges. We’ll explore how Goodman’s reaffirmation of cash earnings guidance may influence the company’s investment narrative...

BioArctic's partner Eisai recently announced the upcoming presentation of extensive new lecanemab (Leqembi) clinical and real-world data at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego from December 1-4, covering long-term treatment outcomes, subcutaneous administration, and real-world registry findings. These disclosures are expected to provide important insights into the long-term effectiveness, patient experience, and potential healthcare resource savings of...

Ameren (AEE) shares have experienced some movement recently, prompting investors to take a closer look at the stock's underlying performance and current valuation. The company's recent returns show modest gains over the past year. See our latest analysis for Ameren. Ameren’s share price has seen a steady upward trend this year, with a 15.73% year-to-date gain. This suggests solid momentum even as shorter-term price returns have dipped. Over the long run, the company has delivered a 14.95%...

While Cracker Barrel Old Country Store, Inc. ( NASDAQ:CBRL ) might not have the largest market cap around , it received...

The Morning Bull - US Market Morning Update Thursday, Nov, 20 2025 US stock futures are pointing higher this morning, with contracts linked to the major indexes rising more than 1% before the opening bell. Two stories are grabbing attention. First, the US economy added just 50,000 jobs in September, much less than usual but still showing some hiring. At the same time, average mortgage rates nudged up to 6.37%, and mortgage applications slumped by over 5%, making it harder for people to buy...

Sienna Senior Living Inc.'s ( TSE:SIA ) robust earnings report didn't manage to move the market for its stock. Our...

Nipro Corporation has announced a second-quarter dividend of ¥10.00 per share for the fiscal year ending March 31, 2026, compared to ¥12.00 per share paid a year earlier, with payments scheduled to begin December 10, 2025. This reduction in the interim dividend signals a shift in how management is approaching capital allocation and could reflect changing expectations for future cash flows. We'll explore how this dividend decrease could influence Nipro's investment narrative and perceptions...

On November 11, 2025, 1&1 AG confirmed its full-year 2025 earnings guidance, projecting stable contract base and service revenue at the previous year’s level of €3,303.1 million, while reporting nine-month sales of €3,016.26 million and a net income decline to €110.71 million compared to the prior year. Despite reaffirming guidance, the company’s drop in net income and near-identical sales year-on-year highlight ongoing operational pressures in a competitive German telecom market. We'll...

ROHM (TSE:6963) lifted its financial projections for the current fiscal year, driven by stronger first-half demand and ongoing investments in digitalization and factory automation. These upward revisions have captured the attention of investors. See our latest analysis for ROHM. ROHM’s renewed outlook and recent innovations, such as integrating its TriC3 gate drive technology to boost energy efficiency in motors, have contributed to strong investor sentiment despite some near-term volatility...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Even though Endeavour Mining plc's ( TSE:EDV ) recent earnings release was robust, the market didn't seem to notice...

The U.S. Food and Drug Administration approval of REDEMPLO marks a significant milestone for Arrowhead Pharmaceuticals (ARWR). This is the company’s first FDA-cleared siRNA therapy and is intended for adults with familial chylomicronemia syndrome. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ breakthrough with REDEMPLO has come amid renewed momentum in the stock, which boasts a 90-day share price return of nearly 88% and a total shareholder return of 108%...

Wolfe Research recently initiated coverage on Corcept Therapeutics with a Peerperform rating, highlighting both the company’s ongoing patent litigation and antitrust concerns, as well as the potential upside from its drug candidate relacorilant ahead of its upcoming PDUFA date for hypercortisolism on December 30, 2025. Although Corcept outperformed expectations for earnings per share in the third quarter of 2025, it reported revenue below analyst forecasts, contributing to investor caution...